1. Home
  2. XPO vs WAT Comparison

XPO vs WAT Comparison

Compare XPO & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPO Inc.

XPO

XPO Inc.

HOLD

Current Price

$143.24

Market Cap

16.4B

ML Signal

HOLD

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$394.93

Market Cap

17.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPO
WAT
Founded
2000
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
16.4B
17.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
XPO
WAT
Price
$143.24
$394.93
Analyst Decision
Strong Buy
Buy
Analyst Count
18
14
Target Price
$147.17
$382.14
AVG Volume (30 Days)
1.3M
531.7K
Earning Date
10-30-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.82
EPS
2.78
10.88
Revenue
$8,068,000,000.00
$3,105,638,000.00
Revenue This Year
$1.59
$7.96
Revenue Next Year
$3.74
$6.32
P/E Ratio
$51.41
$36.30
Revenue Growth
N/A
6.90
52 Week Low
$85.06
$275.05
52 Week High
$161.00
$423.56

Technical Indicators

Market Signals
Indicator
XPO
WAT
Relative Strength Index (RSI) 58.19 61.33
Support Level $130.02 $386.09
Resistance Level $142.64 $403.80
Average True Range (ATR) 5.60 9.63
MACD 0.66 -1.66
Stochastic Oscillator 82.98 53.55

Price Performance

Historical Comparison
XPO
WAT

About XPO XPO Inc.

Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: